FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2568274410> ?p ?o ?g. }

• W2568274410 endingPage "S263" @default.
• W2568274410 startingPage "S263" @default.
• W2568274410 abstract "Circulating tumor cells (CTCs) are prevalent in patients with small cell lung cancer (SCLC) (Hou et al. JCO 2012) but their clinical utility is not known for patients with limited disease (LD) who receive concurrent chemoradiation. Here we report on a patient subgroup who underwent CTC analysis and treatment on the Concurrent ONce-daily (OD) VErsus Twice-daily (BD) RadioTherapy (CONVERT) trial (Faivre-Finn Proc. ASCO 2016) that demonstrated a non-significant difference in the primary endpoint of two-year survival for the OD (51%) and BD (56%) arms. Blood samples (7.5mls) were collected at baseline, prior to any treatment from patients who were enrolled to the CONVERT trial at The Christie Hospital site, Manchester, UK. CTCs were enumerated prospectively using the Cellsearch platform. Patients were randomized 1:1 to receive 45Gy in 30 twice-daily fractions over 3 weeks (Arm 1) or 66Gy in 33 once-daily fractions over 6.5 weeks (Arm 2) starting on day 22 of cycle 1 chemotherapy (4 to 6 cycles of Cisplatin 25mg/m2 days 1-3 or 75mg/m2 day 1 with Etoposide 100mg/m2 days 1-3), followed by prophylactic cranial irradiation if indicated. Radiotherapy planning was with a 3D conformal technique or intensity modulated radiotherapy. Staging by Positron Emission Tomography (PET) was permitted. Standard statistical methods were used to examine associations between CTC number (CTC#), clinical factors and outcomes. Of 547 patients randomized between April 2008 and November 2013, 79 patients (41 in Arm1 and 38 in Arm 2) underwent CTC enumeration (CTC subgroup). The clinical demographics and median overall survival (OS) of the CTC subgroup did not differ significantly from the overall study population. The median number (range) of CTCs per 7.5mls blood for all 79 patients was 1 (0-3750) and for arm 1 and arm 2 patients respectively, 12 (0-164) and 158 (0-3750) (p=0.495). There was a trend for association of CTC# with higher TNM stage. CTC# was significant for survival in univariate and multivariate analysis. The median (95% CI) OS for ≥15 CTCs (n=18) was 6.01 (4.2-11.5) months compared to 30.77 (19.7-39.3) months for < 15 CTCs (n=61), p <0.001. The positive predictive value of CTC# ≥15 for survival ≤ 2 years is 100%, and ≤ 1 year is 72%. CTC# also predicted for worse outcome in patients who had undergone PET staging. CTC# is highly prognostic for poor survival in patients with LD-SCLC, treated with concurrent chemoradiotherapy, and could aid treatment decision making for this disease." @default.
• W2568274410 created "2017-01-13" @default.
• W2568274410 creator A5005765734 @default.
• W2568274410 creator A5007868555 @default.
• W2568274410 creator A5013292737 @default.
• W2568274410 creator A5020778165 @default.
• W2568274410 creator A5021988443 @default.
• W2568274410 creator A5025124724 @default.
• W2568274410 creator A5031033192 @default.
• W2568274410 creator A5045044434 @default.
• W2568274410 creator A5069625387 @default.
• W2568274410 creator A5081133063 @default.
• W2568274410 creator A5089087939 @default.
• W2568274410 date "2017-01-01" @default.
• W2568274410 modified "2023-10-01" @default.
• W2568274410 title "OA05.07 Prognostic Value of Circulating Tumor Cells in Limited-Disease Small Cell Lung Cancer Patients Treated on the CONVERT Trial" @default.
• W2568274410 doi "https://doi.org/10.1016/j.jtho.2016.11.255" @default.
• W2568274410 hasPublicationYear "2017" @default.
• W2568274410 type Work @default.
• W2568274410 sameAs 2568274410 @default.
• W2568274410 citedByCount "1" @default.
• W2568274410 countsByYear W25682744102018 @default.
• W2568274410 crossrefType "journal-article" @default.
• W2568274410 hasAuthorship W2568274410A5005765734 @default.
• W2568274410 hasAuthorship W2568274410A5007868555 @default.
• W2568274410 hasAuthorship W2568274410A5013292737 @default.
• W2568274410 hasAuthorship W2568274410A5020778165 @default.
• W2568274410 hasAuthorship W2568274410A5021988443 @default.
• W2568274410 hasAuthorship W2568274410A5025124724 @default.
• W2568274410 hasAuthorship W2568274410A5031033192 @default.
• W2568274410 hasAuthorship W2568274410A5045044434 @default.
• W2568274410 hasAuthorship W2568274410A5069625387 @default.
• W2568274410 hasAuthorship W2568274410A5081133063 @default.
• W2568274410 hasAuthorship W2568274410A5089087939 @default.
• W2568274410 hasBestOaLocation W25682744101 @default.
• W2568274410 hasConcept C121608353 @default.
• W2568274410 hasConcept C126322002 @default.
• W2568274410 hasConcept C141071460 @default.
• W2568274410 hasConcept C143998085 @default.
• W2568274410 hasConcept C168563851 @default.
• W2568274410 hasConcept C203092338 @default.
• W2568274410 hasConcept C2776256026 @default.
• W2568274410 hasConcept C2776694085 @default.
• W2568274410 hasConcept C2778119113 @default.
• W2568274410 hasConcept C2779013556 @default.
• W2568274410 hasConcept C2779562246 @default.
• W2568274410 hasConcept C45393284 @default.
• W2568274410 hasConcept C500558357 @default.
• W2568274410 hasConcept C509974204 @default.
• W2568274410 hasConcept C61238886 @default.
• W2568274410 hasConcept C71924100 @default.
• W2568274410 hasConceptScore W2568274410C121608353 @default.
• W2568274410 hasConceptScore W2568274410C126322002 @default.
• W2568274410 hasConceptScore W2568274410C141071460 @default.
• W2568274410 hasConceptScore W2568274410C143998085 @default.
• W2568274410 hasConceptScore W2568274410C168563851 @default.
• W2568274410 hasConceptScore W2568274410C203092338 @default.
• W2568274410 hasConceptScore W2568274410C2776256026 @default.
• W2568274410 hasConceptScore W2568274410C2776694085 @default.
• W2568274410 hasConceptScore W2568274410C2778119113 @default.
• W2568274410 hasConceptScore W2568274410C2779013556 @default.
• W2568274410 hasConceptScore W2568274410C2779562246 @default.
• W2568274410 hasConceptScore W2568274410C45393284 @default.
• W2568274410 hasConceptScore W2568274410C500558357 @default.
• W2568274410 hasConceptScore W2568274410C509974204 @default.
• W2568274410 hasConceptScore W2568274410C61238886 @default.
• W2568274410 hasConceptScore W2568274410C71924100 @default.
• W2568274410 hasIssue "1" @default.
• W2568274410 hasLocation W25682744101 @default.
• W2568274410 hasOpenAccess W2568274410 @default.
• W2568274410 hasPrimaryLocation W25682744101 @default.
• W2568274410 hasRelatedWork W2015473806 @default.
• W2568274410 hasRelatedWork W2067245977 @default.
• W2568274410 hasRelatedWork W2090610912 @default.
• W2568274410 hasRelatedWork W2348495938 @default.
• W2568274410 hasRelatedWork W2357406576 @default.
• W2568274410 hasRelatedWork W2389384568 @default.
• W2568274410 hasRelatedWork W2418514417 @default.
• W2568274410 hasRelatedWork W2419189404 @default.
• W2568274410 hasRelatedWork W2468136680 @default.
• W2568274410 hasRelatedWork W1899415052 @default.
• W2568274410 hasVolume "12" @default.
• W2568274410 isParatext "false" @default.
• W2568274410 isRetracted "false" @default.
• W2568274410 magId "2568274410" @default.
• W2568274410 workType "article" @default.